MedTrace Logo

A Phase I Study of the Safety and Immunogenicity of MVA85A in Healthy Gambian Volunteers

NCT00423839 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2007-01-18

No results posted yet for this study

Summary

A Phase I study of the Safety and immunogenicity of MVA85A in healthy Gambian volunteers

Conditions

Interventions

BIOLOGICAL

MVA85A (Tuberculosis vaccine)

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Helen McShane, MD and PhD · University of Oxford

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-03-31
Completion
2005-07-31

Countries

  • The Gambia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00423839 on ClinicalTrials.gov